Aerovate Therapeutics Stock Quote AVTE - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

19.91

Bid

18.00

Ask

31.64

Volume

0.00 Day's Range 0.00

9.41 52 Week Range 32.415

Market Cap

550.888M

Previous Close

19.91

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

201,327

Shares Outstanding

27,668,887

Dividend Yield

PE Ratio

-7.29

Earnings Per Share (EPS)

-2.73

Revenue

Net Profit

-75.52M

Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hyper... Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, a devastating disease impacting people in the United States and Europe. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.aerovatetx.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Aerovate Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker AVTE. The last closing price for Aerovate Therapeutics was $19.91. Over the last year, Aerovate Therapeutics shares have traded in a share price range of $ 9.41 to $ 32.415.

Aerovate Therapeutics currently has 27,668,887 shares outstanding. The market capitalization of Aerovate Therapeutics is $550.89 million. Aerovate Therapeutics has a price to earnings ratio (PE ratio) of -7.29.

Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference

Baseline characteristics reflect a PAH population with significant disease Topline data from Phase 2b portion of IMPAHCT study to be released in June 2024 Enrollment into the Phase 3 portion of...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights

Topline data expected in June 2024 from Phase 2b portion of the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension (PAH) Enrollment continues into the...

Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference

WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of...

Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights

Topline data expected in June 2024 from Phase 2b portion of the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension (PAH) Completed enrollment in the...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	2.11	11.8539325843	17.8	19.92	15.76	352976	18.33868671	CS
4	-1.77	-8.16420664207	21.68	22.48	15.52	256585	18.70970664	CS
12	-4.5	-18.4350675952	24.41	32.415	15.52	201327	22.55758153	CS
26	3.51	21.4024390244	16.4	32.415	15.52	145869	21.76920232	CS
52	3.61	22.1472392638	16.3	32.415	9.41	113089	19.24335317	CS
156	-8.09	-28.8928571429	28	32.415	7.74	103266	18.60415619	CS
260	-8.09	-28.8928571429	28	32.415	7.74	103266	18.60415619	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
VEROVenus Concept Inc	$ 1.46 (148.85%)	3.13M
VSVersus Systems Inc	$ 2.74 (66.06%)	2.99M
VVPRVivoPower International PLC	$ 3.28 (33.88%)	2
FFIEFaraday Future Intelligent Electric Inc	$ 0.6825 (25.46%)	5.95M
VIRXViracta Therapeutics Inc	$ 0.78 (22.85%)	234
DSYBig Tree Cloud Holdings Limited	2.20 (-70.81%)	1.61k
BMEABiomea Fusion Inc	$ 4.67 (-58.56%)	70.17k
VRAXVirax Biolabs Group Ltd	$ 1.52 (-22.84%)	136.13k
XYLOXylo Technology Ltd	$ 1.50 (-19.79%)	200
FRESFresh2 Group Ltd	$ 0.38 (-18.28%)	306
CRKNCrown Electrokinetics Corporation	$ 0.0969 (10.87%)	6.28M
FFIEFaraday Future Intelligent Electric Inc	$ 0.6825 (25.46%)	5.95M
PRSTPresto Technologies Inc	$ 0.0916 (20.69%)	3.33M
VEROVenus Concept Inc	$ 1.46 (148.85%)	3.13M
VSVersus Systems Inc	$ 2.74 (66.06%)	2.99M